

## Monkeypox Suspect, Probable or Confirmed Case Algorithm

### Patient History

- [Signs and Symptoms](#) (prodromal or skin symptoms)
- [Contact](#) of known case? [Exposure risk](#)? Recent travel to a region known to be experiencing monkeypox transmission within the last 21 days?
- [Risk group](#)? (i.e. individuals in a social network experiencing monkeypox activity)
- Vaccinated against smallpox? Vaccine scar present?
  - Last year administered in Canada 1972

### Isolate Immediately if Symptomatic

Notify OCPHO **IMMEDIATELY** by phone at (867) 920-8646

### Public Health Measures

- Follow healthy respiratory practices
- Practice frequent hand hygiene
- Frequently disinfect surfaces
- Avoid contact with others and animals
- Avoid sharing personal items (bed linens, towels, toiletries, food utensils, etc.) until disinfected
- Keep lesions covered and wear a mask if unable to avoid others (i.e., shared household)

If presenting in facility contact facility IPAC  
(867-445-2121 DO NOT text this number)  
– [See NTHSSA protocols](#)

### Public health active daily monitoring

- Of confirmed case or until test result known

### Test

Collect appropriate specimen(s) as per [Gov. Canada](#) or facility protocol

If result of test will be delayed consider initiating public health contact investigation

### Negative Test Result

- If symptomatic rule out other infectious etiology (i.e., varicella)
- Discontinue isolation at healthcare providers discretion

### Positive Test Result

- Continue isolation for 21 days OR until scabs have fallen off and new, intact skin has formed, whichever is longer
- Continue active daily monitoring of case
- Consider active monitoring of other household members until case isolation is discontinued

Public Health Investigation of Contacts  
see [Contact Investigation Form](#)

See Monkeypox Contact Algorithm (next page)

- [Consider Pre-exposure monkeypox vaccine](#) if individual fits eligibility criteria (see next page for further information)

### Public Health Information for Case

- Educate case on complications and when to report to HCP

### Eligibility for Antiviral

- HCP must review risk factors with clinician.
- Contact OCPHO for authorization at (867) 920-8646

### Risk Factors

- Pregnancy
- Children (under 12)
- Anyone immuno-suppressed:
  - HIV
  - Uncontrolled diabetes
  - Anyone on biologics, oral steroid use, Cancer patients (active treatment or not in remission)
- Severe COPD or asthma
- Atopic dermatitis
- Exposure risk for ongoing transmission

Complete PHAC [Case Reporting Form](#)



## Monkeypox Contact Algorithm

### Client is identified as or suspected to be a **contact**

- Complete [risk assessment](#) (Type of exposure, duration, length)

#### Asymptomatic

- Self-monitor for 21 days from last exposure
- Assess eligibility for post-exposure monkeypox vaccine and determine if vaccination with [Imvamune®](#) is appropriate
  - People who have a known [exposure/high-risk exposure contact](#) with someone with monkeypox
  - When the vaccine is used For post-exposure, it should be given within 4 days, but can be given up to 14 days after the last exposure.
- Provide client with information on [public health measures](#)
- A 2<sup>nd</sup> dose of monkeypox vaccine can be offered 28 days later especially if risk factors are present.
- Consider work exclusion for contacts who work with vulnerable populations. Ex. LTCF, healthcare facilities, childcare facilities, congregate living settings

#### Symptomatic

- **Isolate immediately**, arrange for testing and follow Monkeypox Suspect, Probable or Confirmed Case Algorithm as probable case (see other side)

#### Risk Factors

- Pregnancy
- Children (under 12)
- Anyone immuno-suppressed:
  - HIV
  - Uncontrolled diabetes
  - Anyone on biologics, oral steroid use, Cancer patients (active treatment or not in remission)
- Severe COPD or asthma
- Atopic dermatitis
- Exposure risk for ongoing transmission

### Risk Assessment and Pre-Exposure [Monkeypox Vaccine Eligibility](#)

Individuals belonging to certain risk populations may be eligible to receive [Imvamune®](#) as a pre-exposure vaccination.

#### Eligibility Criteria

A) Two-spirited, non-binary, transgender men and women or cis-gender individuals who self-identify **or** have sexual partners who self-identify as belonging to the gay, bisexual and other men who have sex with men (gbMSM) community **AND** at least one of the following:

- Diagnosed with a bacterial sexually transmitted infection (STI) in the past 12 months (e.g. chlamydia, gonorrhea, or syphilis);
- Recently had 2 or more sexual partners or may be planning to;
- Recently attended venues for sexual contact (e.g. bathhouses, sex clubs) or may be planning to, or who work/volunteer in these settings;
- Recently had anonymous/casual sex (e.g. using hook up apps) or may be planning to;
- A sexual contact of an individual who engages in sex work.

B) Anyone who engages in sex work or may be planning to.

C) Household and/or sexual contacts of people who are eligible for pre-exposure monkeypox vaccination – listed above in parts (a) or (b) – **AND** are immunocompromised or are pregnant. These individuals should be assessed by a healthcare provider.

